Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

618 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study.
Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U, Bacher U, Staber PB, Mazzeo P, Leng C, Böckle D, Hölscher AS, Kauer J, Rotter N, Vucinic V, Rudzki JD, Nachbaur D, Bücklein VL, Schnetzke U, Krämer I, Wille K, Hasse A, von Tresckow B, Hänel M, Koenecke C, Velazquez GF, Viardot A, Schmid C, Thurner L, Wolf D, Subklewe M, Dreyling M, Dreger P, Dietrich S, Keller U, Jaeger U, Greil R, Pabst T, Lenz G, Chapuy B. Shumilov E, et al. Among authors: lenz g. Blood Adv. 2024 Dec 11:bloodadvances.2024014903. doi: 10.1182/bloodadvances.2024014903. Online ahead of print. Blood Adv. 2024. PMID: 39661985
Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study.
Berning P, Shumilov E, Maulhardt M, Boyadzhiev H, Kerkhoff A, Call S, Reicherts C, Saidy AO, Aydilek E, Hoffmann M, Novak U, Daskalakis M, Schmitz N, Stelljes M, Wulf G, Bacher U, Lenz G, Pabst T. Berning P, et al. Among authors: lenz g. Hemasphere. 2024 Mar 20;8(3):e54. doi: 10.1002/hem3.54. eCollection 2024 Mar. Hemasphere. 2024. PMID: 38510993 Free PMC article.
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma).
Tournilhac O, Altmann B, Friedrichs B, Bouabdallah K, Leclerc M, Cartron G, Turlure P, Reimer P, Wagner-Drouet E, Sanhes L, Houot R, Roussel M, Kroschinsky F, Dreger P, Viardot A, de Leval L, Rosenwald A, Gaulard P, Wulf G, Villate A, Latiere C, Elmaagacli A, Glass B, Poeschel V, Damaj G, Sibon D, Durot E, Bilger K, Banos A, Haenel M, Dreyling M, Keller U, Tiab M, Drenou B, Cornillon J, Nguyen S, Robin M, Nickelsen M, Trümper L, Lenz G, Ziepert M, Schmitz N; French Lymphoma Study Association (LYSA), the Société Francophone de greffe de moelle et Thérapie Cellulaire (SFGM-TC), and the German Lymphoma Alliance (GLA). Tournilhac O, et al. Among authors: lenz g. J Clin Oncol. 2024 Nov 10;42(32):3788-3794. doi: 10.1200/JCO.24.00554. Epub 2024 Sep 13. J Clin Oncol. 2024. PMID: 39270145 Clinical Trial.
CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges.
Werner R, Haug A, Buske C, Heidegger S, Illert AL, Bassermann F, Herhaus P, Buck A, Duell J, Topp MS, Kraus S, Einsele H, Lapa C, Raderer M, Lenz G, Habringer S, von Tresckow B, Keller U. Werner R, et al. Among authors: lenz g. Nuklearmedizin. 2024 Apr;63(2):57-61. doi: 10.1055/a-2194-9965. Epub 2024 Jan 8. Nuklearmedizin. 2024. PMID: 38190998 Free PMC article.
Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.
Stelljes M, Raffel S, Alakel N, Wäsch R, Kondakci M, Scholl S, Rank A, Hänel M, Spriewald B, Hanoun M, Martin S, Schwab K, Serve H, Reiser L, Knaden J, Pfeifer H, Marx J, Sauer T, Berdel WE, Lenz G, Brüggemann M, Gökbuget N, Wethmar K. Stelljes M, et al. Among authors: lenz g. J Clin Oncol. 2024 Jan 20;42(3):273-282. doi: 10.1200/JCO.23.00546. Epub 2023 Oct 26. J Clin Oncol. 2024. PMID: 37883727 Clinical Trial.
Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress.
Gomez Solsona B, Horn H, Schmitt A, Xu W, Bucher P, Heinrich A, Kalmbach S, Kreienkamp N, Franke M, Wimmers F, Schuhknecht L, Rosenwald A, Zampieri M, Ott G, Lenz G, Schulze-Osthoff K, Hailfinger S. Gomez Solsona B, et al. Among authors: lenz g. Blood Adv. 2023 Dec 26;7(24):7433-7444. doi: 10.1182/bloodadvances.2023010964. Blood Adv. 2023. PMID: 37934892 Free PMC article.
Diffuse Large B-Cell Lymphoma and Related Entities.
Ernst M, Dührsen U, Hellwig D, Lenz G, Skoetz N, Borchmann P. Ernst M, et al. Among authors: lenz g. Dtsch Arztebl Int. 2023 Apr 28;120(17):289-296. doi: 10.3238/arztebl.m2023.0035. Dtsch Arztebl Int. 2023. PMID: 36942797 Free PMC article.
618 results